Metsera Inc., a clinical-stage biopharmaceutical company, has announced it will present new research at the 85th Scientific Sessions of the American Diabetes Association. The company will showcase its next-generation obesity portfolio, including clinical and preclinical findings from its lead program, MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist. The presentations will include clinical data from MET-097i's completed Phase 1/2 trial, alongside preclinical data on MET-233i, a monthly, ultra-long acting amylin analog. These presentations aim to highlight Metsera's scalable and differentiated approaches to treating overweight and obesity. Further details about the company's presence at the ADA meeting can be found on their website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。